Wells Fargo Maintains Overweight on MediWound, Raises Price Target to $8
Wells Fargo analyst Jacob Hughes maintains MediWound (NASDAQ:MDWD) with a Overweight and raises the price target from $7 to $8.
The Daily Biotech Pulse: Pfizer-BioNTech’s COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio’s AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For May 17, 2022
Companies Reporting Before The Bell
• On Holding (NYSE:ONON) is likely to report earnings for its first quarter.
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
MediWound Receives Notice Of Allowance For U.S. Patent Titled ‘DEBRIDING COMPOSITION FOR TREATING WOUNDS’
https://patentcenter.uspto.gov/#!/applications/16072955/ifw/docs
Aegis Capital Maintains Buy on MediWound, Lowers Price Target to $7
Aegis Capital analyst Nathan Weinstein maintains MediWound (NASDAQ:MDWD) with a Buy and lowers the price target from $9 to $7.
The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
MediWound Earnings Preview
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement.
Analysts estimate that MediWound will report an earnings per share (EPS) of $-0.15.
